Carotid Endarterectomy
Carotid endarterectomy decisions anchored to the qualifying ischemic event, stenosis range with proven operative benefit, treatment timing, and center 30-day stroke and death rate. The chapter frames patient selection, operative technique, and perioperative care for symptomatic and asymptomatic disease.
Choose a chapter overview or a specialist discussion. Each recording follows this published edition.
General medical education, not patient-specific advice.
Choose an audio editionDefinition and clinical presentation
Carotid is an open surgical procedure designed to remove atheromatous plaque from the carotid bifurcation to prevent future stroke, first described for recurrent hemispheric ischemia in 1954 . The procedure is evaluated across two distinct clinical presentations:
- Symptomatic disease: recent attributable ipsilateral retinal or hemispheric ischemia, including transient ischemic attack, amaurosis fugax or stroke. Stroke severity determines the intervention pathway, not whether the disease is symptomatic.
- Asymptomatic disease: detected incidentally or by screening without recent ipsilateral neurologic symptoms.
Perioperative antiplatelet treatment should follow the CEA-specific pathway in Chapter 30. A short DAPT course for selected minor stroke or high-risk TIA is not a universal requirement before CEA, nor a reason to delay otherwise indicated urgent surgery.
Treatment decision and operative thresholds
The treatment decision rests on validating the symptom link, measuring stenosis severity, confirming adequate life expectancy, and proving acceptable institutional perioperative complication rates.
- Symptomatic, average surgical risk
- Recommended action
- CEA promptly, ideally within 14 days when appropriate; apply the stable-stroke, recurrent-symptom and major-injury pathways in Chapter 30
- Stenosis severity
- 70 to 99% conventional NASCET stenosis
Citation - Symptomatic, moderate stenosis
- Recommended action
- Consider CEA individually using expected benefit, timing and procedural risk
- Stenosis severity
- 50 to 69%
Citation - Symptomatic quality gate
- Recommended action
- ESVS: <6% at 30 days. ESO expert consensus: ideally <4% in hospital. These are different observation windows.
- Stenosis severity
- Independently assessed stroke or death
Citation - Asymptomatic, acceptable surgical risk
- Recommended action
- SVS uses ≥70%; ESVS also considers selected 60 to 99% disease with additional risk features and expected survival exceeding five years. Reassess expected benefit in light of contemporary trials rather than treating stenosis alone as an indication.
- Stenosis severity
- Guideline-specific selection
Citation - Asymptomatic quality gate
- Recommended action
- ESVS: ≤3% at 30 days. ESO expert consensus: ideally <2% in hospital. A safety benchmark alone does not establish benefit.
- Stenosis severity
- Independently assessed stroke or death
Citation
Use Chapter 30 for the shared selection and timing algorithm. The CEA-specific assessment here should establish that open reconstruction is appropriate and feasible, and identify operative, antiplatelet and follow-up requirements. A hostile neck or high surgical risk is relevant to stent selection but is not the only situation in which CAS may be considered.
Symptomatic disease and intervention timing
Carotid endarterectomy delivers its greatest absolute benefit in high-grade symptomatic stenosis. In the NASCET trial, endarterectomy for symptomatic 70 to 99% stenosis yielded an approximate 17 percentage-point absolute risk reduction in 2-year ipsilateral stroke compared to medical therapy . The ECST trial, using a different measurement method, demonstrated an approximate 11.6% absolute reduction in 3-year major stroke or death for patients with >= 80% stenosis by the ECST criteria .
Benefit in symptomatic 50 to 69% stenosis is smaller and requires individual assessment. The 1998 NASCET report estimated five-year ipsilateral stroke at 15.7% after CEA versus 22.2% with medical therapy. The pooled five-year NNT estimates of 9 for men and 36 for women concerned patients with ≥50% stenosis, not exclusively the moderate group or every symptomatic stenosis band. The pooled endpoint included ipsilateral ischemic stroke and any perioperative stroke or death; sex should not function as a stand-alone exclusion.
Benefit is time-sensitive. The pooled NASCET/ECST timing analysis used the interval from the last event to randomization, not randomized assignment to an operation date. EXPRESS associated a rapid assessment-and-treatment pathway with less early recurrent stroke; it did not isolate the effect of CEA. For appropriate symptomatic candidates, early CEA remains the aim, with the conditional timing pathways in Chapter 30 distinguishing stable stroke, recurrent symptoms and major established injury.
Asymptomatic disease
In ACAS, patients with asymptomatic ≥60% stenosis had estimated five-year ipsilateral stroke plus perioperative stroke-or-death risks of 5.1% with CEA and 11.0% with trial-era medical therapy, an absolute difference of 5.9 percentage points. This is not an estimate of all strokes alone or of benefit over current intensive medical management.
ACST-1 reported 30-day stroke or death in 3.0% of 1979 CEAs performed during the trial, not solely operations in the immediate-allocation arm. Excluding procedural events, five-year stroke risks were 4.1% with immediate CEA and 10.0% with deferred intervention. Including procedural events, the net risks were 6.9% versus 10.9% at five years and 13.4% versus 17.9% at ten years. The net comparison is the relevant one when describing prophylactic benefit; it does not prove that one institutional cutoff guarantees benefit in every contemporary patient.
Modality selection: endarterectomy versus stenting
CEA is generally preferred for suitable standard-risk symptomatic patients, particularly older patients. CAS may also be considered in selected younger symptomatic patients; it is not restricted absolutely to high surgical risk or a hostile neck. Symptomatic stenting carries a substantial early hazard; the EVA-3S trial was terminated early when stenting demonstrated a 30-day stroke or death rate of 9.6% compared to 3.9% for endarterectomy, an approximate 2.5-fold relative risk increase .
Overall comparative evidence defines an explicit tradeoff boundary. In the CREST trial, 4-year primary composite outcomes were similar between modalities overall, but stenting caused more periprocedural strokes, while endarterectomy caused more periprocedural myocardial infarctions and carries cranial-nerve injury risk . A strong age interaction governs selection: patients aged 70 years or older experience lower periprocedural stroke rates with endarterectomy than with stenting, establishing open surgery as the preferred modality in this older demographic . ACST-2’s selected asymptomatic population had similar five-year non-procedural fatal or disabling stroke after CEA and CAS, but procedural non-disabling strokes were more frequent after CAS. This was not a comparison with medical therapy alone.
Operative technique and surveillance
Conventional CEA uses a longitudinal arteriotomy with plaque removal and reconstruction, ordinarily with patch closure rather than routine primary closure. Eversion CEA instead transects the ICA obliquely at its origin, removes plaque by eversion and reimplants the artery after checking the distal endpoint. Choice of reconstruction, shunting and monitoring should be explicit. Evidence comparing patching with primary closure supports possible reductions in ipsilateral stroke and restenosis, but its certainty is limited.
Surveillance should look for restenosis, occlusion, pseudoaneurysm and recurrent symptoms. SVS’s 2018 follow-up recommendation uses a baseline duplex preferably within three months, six-monthly studies for two years and then annual assessment until stable, with continued periodic lifelong surveillance. ESVS does not find evidence for routine duplex surveillance of every patient and discusses selective follow-up. State the adopted policy rather than presenting a hybrid as a single guideline schedule.
Restenosis comparisons depend on severity: pooled trials found more ≥50% restenosis or occlusion after CAS, but did not establish a significant difference in severe ≥70% restenosis. A detected lesion should prompt review of symptoms, imaging, original reconstruction and whether reintervention has an indication.
Areas of controversy
CREST-2 results are available: the CEA comparison did not show a statistically significant advantage for adding CEA to intensive medical management on its four-year primary outcome. A nonsignificant comparison is not proof that CEA has no benefit, and the separate positive CAS comparison is not evidence that CAS beat CEA. Chapter 30 gives both comparisons and the distinct ECST-2 interim results. Patient selection after these trials remains a clinical and guideline-interpretation question.
No patch material is established as universally best. The 2021 review’s low-certainty Dacron-versus-PTFE signal for long-term stroke or death favoured , not Dacron; its pseudoaneurysm evidence was very uncertain. The August 2026 update compares synthetic with biological patches and still leaves important rare harms uncertain. Material choice should not be based on a reversed comparison or described as settled by definitive vein-patch harm.
For CEA performed under general anaesthesia, the 2022 shunting review found insufficient evidence to choose routine, selective or no shunting, or to identify a consistently superior monitoring method. Some routine-versus-no-shunt outcomes favoured shunting in low-certainty analyses, so it is inaccurate to describe all comparisons as showing no significant difference. The updated review included no new trials; shunting and monitoring policy therefore remains an explicit operative decision rather than a proven universal rule.
Further reading
- Patches of different types for carotid patch angioplasty. (2021). Patch-material evidence for carotid endarterectomy; not whether CEA is indicated.
References
- 1.Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia.PubMed-indexed article1954
EASTCOTT HH, PICKERING GW, ROB CG. Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. Lancet. 1954;267(6846):994-6. doi:10.1016/s0140-6736(54)90544-9. PMID:13213095.
- 2.2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. 2021.PubMed-indexed articleClinical practice guideline2021
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. 2021. doi:10.1161/str.0000000000000375.
- 3.Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis. 1991.PubMed-indexed articleRandomized controlled trial1991
Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis. 1991. doi:10.1056/nejm199108153250701.
- 4.European Stroke Organisation Carotid Endarterectomy and Stenting Guideline (Bonati et al, ESJ 2021).PubMed-indexed articleClinical practice guideline2021
European Stroke Organisation Carotid Endarterectomy and Stenting Guideline (Bonati et al, ESJ 2021). doi:10.1177/23969873211012121.
- 5.Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease.PubMed-indexed articleClinical practice guideline2022
AbuRahma AF, Avgerinos ED, Chang RW, Darling RC 3rd, Duncan AA, Forbes TL, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg. 2022;75(1S):4S-22S. doi:10.1016/j.jvs.2021.04.073. PMID:34153348.
- 6.Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. 2023.PubMed-indexed articleClinical practice guideline2023
Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. 2023. doi:10.1016/j.ejvs.2022.04.011.
- 7.10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. 2010.PubMed-indexed articleRandomized controlled trial2010
10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. 2010. doi:10.1016/s0140-6736(10)61197-x.
- 8.Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). 1998.PubMed-indexed articleRandomized controlled trial1998
Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). 1998. doi:10.1016/s0140-6736(97)09292-1.
- 9.Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. 2004.PubMed-indexed articleMeta-analysis / systematic review2004
Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. 2004. doi:10.1016/S0140-6736(04)15785-1. PMID:15043958.
- 10.Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison.PubMed-indexed article2007
Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370(9596):1432-42. doi:10.1016/S0140-6736(07)61448-2. PMID:17928046.
- 11.
- 12.Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. 1995.PubMed-indexed articleRandomized controlled trial1995
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. 1995. doi:10.1001/jama.273.18.1421.
- 13.Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis.PubMed-indexed articleRandomized controlled trial2006
Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006;355(16):1660-71. doi:10.1056/NEJMoa061752. PMID:17050890.
- 14.Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis.PubMed-indexed articleMeta-analysis / systematic review2020
Müller MD, Lyrer P, Brown MM, Bonati LH. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. Cochrane Database Syst Rev. 2020;2(2):CD000515. doi:10.1002/14651858.CD000515.pub5. PMID:32096559.
- 15.Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. 2021.PubMed-indexed articleRandomized controlled trial2021
Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. 2021. doi:10.1016/s0140-6736(21)01910-3.
- 16.Patch angioplasty versus primary closure for carotid endarterectomy.PubMed-indexed articleMeta-analysis / systematic review2009
Rerkasem K, Rothwell PM. Patch angioplasty versus primary closure for carotid endarterectomy. Cochrane Database Syst Rev. 2009;2009(4):CD000160. doi:10.1002/14651858.CD000160.pub3. PMID:19821267.
- 17.
- 18.Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting).PubMed-indexed articleMeta-analysis / systematic review2014
Chongruksut W, Vaniyapong T, Rerkasem K. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). Cochrane Database Syst Rev. 2014;2014(6):CD000190. doi:10.1002/14651858.CD000190.pub3. PMID:24956204.
- 19.Howard VJ, Meschia JF, Lal BK, et al. Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. Int J Stroke. 2017;12(7):770-778.PubMed-indexed article2017
Howard VJ, Meschia JF, Lal BK, Howard G, Jones MR, Lackland DT, Liapis CD, Mohr JP, Munch KE, Cutlip DE, Brott TG. Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. Int J Stroke. 2017 Oct;12(7):770-778.
- 20.Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial CollaboratorsPubMed-indexed article1998
Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators doi:10.1056/NEJM199811123392002.
- 21.
- 22.
- 23.
- 24.Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trialPubMed-indexed article2025
Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial doi:10.1016/S1474-4422(25)00107-3.
- 25.
- 26.Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting)Cochrane Library2022
Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting) doi:10.1002/14651858.CD000190.pub4.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.